Healthcare Oct 05, 2021 09:50 AM (GMT+8) · EqualOcean
Yiouda health learned on the 5th that Takeda reached a cooperation agreement with selecta with more than US $1.1 billion on the 4th US time. Prior to this, selecta had just experienced the layoff turmoil caused by the setback of gout drugs. According to foreign media reports, the cooperation mainly focused on the immtor platform and reached a milestone agreement worth $1.12 billion. But there are not many specific details. Both parties kept silent on the advance payment and did not disclose the specific cooperation schedule. More than a month ago, Takeda also had a layout at the gene therapy track. It reached a global cooperation and licensing agreement with Geneva sciences to develop a new non viral vector gene therapy for rare liver diseases by using Geneva's proprietary lipid nanoparticles (LNP) technology platform. This is the second cooperation between the two sides.